The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Review Article

The Moreton Lecture Series: The Renin-Angiotensin-Aldosterone System—Physiology, Pathophysiology, and Pharmacological Inhibition

Authors: Prem Patel, MD, Jessica Ammon, DO, Sean Battle, MD, Donald J. DiPette, MD

Abstract

The renin-angiotensin-aldosterone system (RAAS) is a complex regulator comprising hormones, proteins, and enzymes. The discovery of the RAAS and its pharmacological manipulation has been essential in the management of cardiovascular diseases, including hypertension. Beyond the benefits of hypertension, RAAS inhibition has implications for heart failure, atherosclerotic disease, and kidney disease. This review discusses the history and mechanism of RAAS inhibition, cardiovascular benefits, affordability, and potential future pharmacological therapies.

 
Posted in: Hypertension16

Full Article

Having trouble viewing the article content below? Click here to open it directly.

Images

Download Image

References

1. Fountain JH, Kaur J, Lappin SL. Physiology, Renin Angiotensin System. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.
 
2. Moser M. Historical perspectives on the management of hypertension. J Clin Hypertens (Greenwich) 2006;8(8 Suppl 2):15-39.
 
3. Saklayen MG, Deshpande NV. Timeline of history of hypertension treatment. Front Cardiovasc Med 2016;3:3.
 
4. Moser M. Evolution of the treatment of hypertension from the 1940s to JNC V. Am J Hypertens 1997;10:2S-8S.
 
5. Kolkhof P, Bärfacker L. 30 years of the mineralcorticoid receptor. Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol 2017;234:T125-T140.
 
6. Williams B. Drug discovery in renin-angiotensin system intervention: past and future. Ther AdvCardiovascDis2016;10:118-125.
 
7. Adam M. Integrating research and development: the emergence of rational drug design in the pharmaceutical industry. Stud Hist Philos Biol Biomed Sci 2005;36:513-537.
 
8. Brown MJ. Aliskiren. Circulation 2008;118:773-784.
 
9. Ma TKW, KamKKH, YanBP, et al. Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010;160:1273–1292.
 
10. Mentz RJ, Bakris GL, Waeber B, et al. The past, present and future of renin–angiotensin aldosterone system inhibition. Int J Cardiol 2013;167:1677–1687.
 
11. Mehta JK, Kaur G, Buttar HS, et al. Role of the renin–angiotensin system in the pathophysiology of coronary heart disease and heart failure: diagnostic biomarkers and therapy with drugs and natural products. Front Physiol 2023;14:1034170.
 
12. Nehme A, Zibara K. Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection. Hypertens Res 2017;40:903–909.
 
13. Forrester SJ, Booz GW, Sigmund CD, et al. Angiotensin II signal transduction: an update on mechanisms of physiology and pathophysiology. Physiol Rev 2018;98:1627–1738.
 
14. Kolakovic A, Zivkovic M, Stankovic A, et al. Involvement of the renin-angiotensin system in atherosclerosis. In: A.N. Tolekova, ed., Renin-Angiotensin System- Past, Present and Future, IntechOpen, https://www.intechopen.com/chapters/53998. Published 2017. Accessed February 2024.
 
15. Poznyak AV, Bharadwaj D, Prasad G, et al. Renin-angiotensin system in pathogenesis of atherosclerosis and treatment of CVD. IntJMolSci2021;22:6702.
 
16. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575–1581.
 
17. Fizazi K, Foulon S, CarlesJ, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, Phase 3 study with a 2 2factorialdesign.Lancet 2022; 399:1695–1707.
 
18. Leong DP, McMurray JJV, Joseph PG, et al. From ACE inhibitors/ARBs to ARNIs in coronary artery disease and heart failure (part 2/5). J Am Coll Cardiol 2019;74:683–698.
 
19. McMurray JJV, Packer M, Desai AS, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993–1004.
 
20. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–1906.
 
21. Pitt B, Remme W, ZannadF, etal. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309–1321.
 
22. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383:2219–2229.
 
23. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–1675.
 
24. Perrone-Filardi P, Paolillo S, Agostoni P, et al. Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. Eur J Intern Med 2022;102:8–16.
 
25. Bhandari S, Mehta S, Khwaja A, et al. Renin–angiotensin system inhibition in advanced chronic kidney disease. N Engl J Med 2022;387:2021–2032.
 
26. Kobori H, Mori H, Masaki T, et al. Angiotensin II blockade and renal protection. Curr Pharm Design 2013;19:3033–3042.
 
27. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244–252.
 
28. Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano Di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 1998; 352:1252–1256.
 
29. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-ConvertingEnzymeInhibition in Progressive Renal Insufficiency Study Group. NEnglJMed1996;334: 939–945.
 
30. Chawla T, Sharma D, Singh A. Role of the renin angiotensin system in diabetic nephropathy. World J Diabetes 2010;1:141–145.
 
31. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421–426.
 
32. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456–1462.
 
33. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892–1903.
 
34. Tuttle, KR, Sibylle JH, Canziani ME, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, Phase 2 trial. Lancet 2024;403:379–390.
 
35. Chang TE, Ritchey MD, Park S, et al. National rates of nonadherence to antihypertensive medications among insured adults with hypertension, 2015. Hypertension 2019;74: 1324–1332.
 
36. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155: 772–779.
 
37. Buffet L, Ricchetti C. Chronic kidney disease and hypertension: a destructive combination. US Pharm 2012;37:26-29.
 
38. Ritchey M, Chang A, Powers C, et al. Vital Signs: disparities in antihypertensive medication nonadherence among Medicare Part D beneficiaries- United States, 2014. MMWR Morb Mortal Wkly Rep 2016;65:967–976.
 
39. Vawter L, Tong X, Gemilyan M, et al. Barriers to antihypertensive medication adherence among adults–United States, 2005. J Clin Hypertens 2008;10:922-929.
 
40. Johansen ME, Byrd JB. Total and out-of-pocket expenditures on antihypertensive medications in the United States, 2007-2019. Hypertension 2021;78:1662-1664.
 
41. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA 2004;291:1850-1856.
 
42. Chen R, Suchard MA, Krumholz HM, et al. Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study. Hypertension 2021;78:591-603.
 
43. Potier L, Roussel R, Elbez Y, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart 2017;103:1339-1346.
 
44. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction. Circulation 2006;114:838–854.
 
45. Vega IL. ACE inhibitors vs ARBs for primary hypertension. Am Fam Physician 2015;91: 522-523.
 
46. Gallo G, Volpe M, Rubattu S. Angiotensin receptor blockers in the management of hypertension: a real-world perspective and current recommendations. Vasc Health Risk Manag 2022;18:507-515.
 
47. Egocheaga MI, Drak Y, Otero V. Classical nephroprotection: renin angiotensin aldosterone system inhibitors. Semergen 2023;49(Suppl 1):102018.
 
48. Rutkowski B, Tylicki L. Nephroprotective action of renin-angiotensin-aldosterone system blockade in chronic kidney disease patients: the landscape after ALTITUDE and VA NEPHRON-D trials. J Ren Nutr 2015;25:194-200.
 
49. Bakris GL, Saxena M, Gupta A, et al. RNA interference with zilebesiranfor mild to moderate hypertension: the KARDIA-1 randomized clinical trial. JAMA 2024;331:740-749.